Sialyl-Lewis A carbohydrate epitope (CA19-9)

Sialyl-Lewis A (sLe(a)), commonly referred to as the CA19-9 carbohydrate epitope, is a tetrasaccharide (Neu5Ac-alpha-2,3-Gal-beta-1,3-[Fuc-alpha-1,4]-GlcNAc) typically conjugated to proteins or lipids on the cell surface. It serves as a high-affinity ligand for E-selectin, facilitating the tethering and rolling of cells on vascular endothelium, a process essential for both leukocyte trafficking and the metastatic spread of cancer cells (Magnani, 2004, Archives of Biochemistry and Biophysics). While present at low levels in the secretory epithelium of the pancreas, gallbladder, and digestive tract, CA19-9 is significantly overexpressed in various adenocarcinomas, most notably pancreatic ductal adenocarcinoma (PDAC). In clinical practice, CA19-9 is the gold-standard serum biomarker for monitoring disease progression and treatment response in pancreatic cancer patients (Goonetilleke & Siriwardena, 2007, European Journal of Surgical Oncology). Therapeutic strategies targeting CA19-9 include monoclonal antibodies like MVT-5873, which can induce immune-mediated tumor cell killing via ADCC and CDC (Slovin et al., 2019, Journal of Clinical Oncology). Additionally, novel approaches such as antibody-drug conjugates (ADCs) and CAR-T cell therapies are being developed to deliver potent cytotoxic effects directly to CA19-9-expressing tumor cells. However, therapeutic application is complicated by the antigen's expression in some normal tissues and the fact that approximately 5-10% of the population with a Lewis-negative blood group phenotype cannot synthesize the epitope.

Other names

Cancer antigen 19-9sLe(a)Sialyl-Lewis ASialyl-LeaNeu5Ac-alpha-2,3-Gal-beta-1,3-(Fuc-alpha-1,4)-GlcNAc

Monoclonal antibodies target the epitope to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), or serve as delivery vehicles for radioisotopes and cytotoxic payloads.